Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease

Post time 11 min. ago

journal：American Journal of Gastroenterology

Authors：Michael D. Kappelman; Sruthi Adimadhyam; Laura Hou; Audrey E. Wolfe; Samantha Smith; Andrew L. Simon; rick Moyneur; Juliane S. Reynolds; Sengwee Toh; Angela Dobes; Lauren E. Parlett; Kevin Haynes; Mano Selvan; Qianli Ma; Vinit Nair; Jessica Burris; Jennifer E. Dorand; Ghadeer K. Dawwas; James D. Lewis; Millie D. Long

Published date：2023-4-

DOI：10.14309/ajg.0000000000002068

PDF link：https://www.ovid.com/10.14309/ajg.0000000000002068

Article link：https://doi.org/10.14309/ajg.0000000000002068

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 5 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease